Three new orbifloxacin multicomponent crystal forms towards pharmaceutical improvement

Nenhuma Miniatura disponível

Data

2020

Autores

Viana, Olimpia Maria Martins Santos
Freitas, Jennifer Tavares Jacon
Checchinato, Monalisa Bitencourt da Silva
Martins, Felipe Terra
Doriguetto, Antonio Carlos

Título da Revista

ISSN da Revista

Título de Volume

Editor

Resumo

Orbifloxacin (ORBI) is a third-generation synthetic fluoroquinolone used as an antimicrobial veterinary drug for the treatment of gastrointestinal and respiratory infections. Structural information about this drug is restricted to a hemihydrate containing ORBI as a zwitterion, which is the crystal form expected to be present in veterinary solid oral formations. Since the major problem with the ORBI hemihydrate form is its poor solubility and structure conservation upon dehydration, leading to uncontrollable water contents in the active pharmaceutical ingredient (API), we present here for the first time the crystal structures of three ORBI multicomponent crystal forms including two salt solvates and one cocrystal salt solvate: a hydrochloride salt monohydrate (1), a nitrate salt monohydrate (2) and a phosphoric acid hemi-cocrystal of the dihydrogen phosphate salt monohydrate (3). The latter form presents a very interesting multicomponent crystal feature having phosphate species either as a counter-ion or a neutral coformer. Pure crystalline samples of 1–3 were obtained and characterised by powder X-ray diffraction, infrared spectroscopy, thermogravimetry and differential thermal analyses. We have provided here a full analytical dataset for three new multicomponent solid forms of orbifloxacin, which may improve drug solubility and mitigate the possible drawback of inconsistent water load inherent to its hydrated free-base form.

Descrição

Palavras-chave

Orbifloxacin, Multicomponent solid forms, Structural determination, Crystal, Pharmaceutical compound

Citação

SANTOS, Olimpia Maria Martins et al. Three new orbifloxacin multicomponent crystal forms towards pharmaceutical improvement. Journal of Molecular Structure, Amsterdam, v. 1217, e128371, 2020. DOI: 10.1016/j.molstruc.2020.128371. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0022286020306967?via%3Dihub. Acesso em: 14 nov. 2023.